J&J’s Topamax, Risperdal Get Boost From Dual Eligible Shift To Part D
The movement of Medicare and Medicaid dual-eligible patients to Medicare Part D provided Johnson & Johnson a one-time benefit on certain products
You may also be interested in...
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency
A bill introduced by Rep. Bobby Rush, D-Ill., banning "reverse" settlements between brand and generic companies would give the Federal Trade Commission the power to allow any such agreement it deems furthers market competition